董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jean Francois Pariseau | 男 | Director | 50 | 未披露 | 未持股 | 2019-12-31 |
| Arun Menawat | 男 | Chief Executive Officer and Director | 65 | 85.57万美元 | 未持股 | 2019-12-31 |
| Brian Ellacott | 男 | Director | 62 | 3.62万美元 | 未持股 | 2019-12-31 |
| Steve Forte | 男 | Director | 40 | 未披露 | 未持股 | 2019-12-31 |
| Linda Maxwell | 女 | Director | 45 | 1.88万美元 | 未持股 | 2019-12-31 |
| Arthur Rosenthal | 男 | Director | 73 | 3.52万美元 | 未持股 | 2019-12-31 |
| Kenneth Galbraith | 男 | Director | 57 | 4.76万美元 | 未持股 | 2019-12-31 |
| Kenneth Galbraith | 男 | Director | 57 | 未披露 | 未持股 | 2019-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Arun Menawat | 男 | Chief Executive Officer and Director | 65 | 85.57万美元 | 未持股 | 2019-12-31 |
| Mathieu Burtnyk | 男 | Vice-President of Clinical Affairs | 38 | 未披露 | 未持股 | 2019-12-31 |
| Aaron Davidson | 男 | Chief Financial Officer and Senior Vice President of Corporate Development | 51 | 未披露 | 未持股 | 2019-12-31 |
| Rashed Dewan | 男 | Vice President of Finance | 52 | 21.61万美元 | 未持股 | 2019-12-31 |
| Guruprit Singh | 女 | Vice President of Regulatory Affairs and Product Management | 54 | 22.47万美元 | 未持股 | 2019-12-31 |
| Aaron Davidson | 男 | Chief Financial Officer and Senior Vice President of Corporate Development | 51 | 112.25万美元 | 未持股 | 2019-12-31 |
董事简历
中英对照 | 中文 | 英文- Jean Francois Pariseau
-
Jean Francois Pariseau，自2018年7月起担任Amage Ventures的联合创始人兼合伙人；自2001年7月至2018年6月担任风险投资公司BDC Capital梦百合Fund的合伙人。
Jean Francois Pariseau,Co-Founder and Partner at Amplitude Ventures since July 2018; Partner, BDC Capital Healthcare Fund, a venture capital company since July 2001 to June 2018. - Jean Francois Pariseau，自2018年7月起担任Amage Ventures的联合创始人兼合伙人；自2001年7月至2018年6月担任风险投资公司BDC Capital梦百合Fund的合伙人。
- Jean Francois Pariseau,Co-Founder and Partner at Amplitude Ventures since July 2018; Partner, BDC Capital Healthcare Fund, a venture capital company since July 2001 to June 2018.
- Arun Menawat
-
Arun Menawat，自2016年8月起担任公司首席执行官兼董事；2003年至2016年担任Novadaq TechnologiesInc.董事长，总裁兼首席执行官。
Arun Menawat,Chief Executive Officer and Director of the Company since August 2016; Chairman, President and Chief Executive Officer of Novadaq Technologies Inc. from 2003 to 2016. - Arun Menawat，自2016年8月起担任公司首席执行官兼董事；2003年至2016年担任Novadaq TechnologiesInc.董事长，总裁兼首席执行官。
- Arun Menawat,Chief Executive Officer and Director of the Company since August 2016; Chairman, President and Chief Executive Officer of Novadaq Technologies Inc. from 2003 to 2016.
- Brian Ellacott
-
Brian Ellacott自2017年12月起担任Belmont Instrument首席执行官；2013年7月至2017年9月担任Laborie Medical Technology首席执行官。
Brian Ellacott,Chief Executive of Officer Belmont Instrument since December 2017; Chief Executive Officer of Laborie Medical Technology July 2013 to September 2017. - Brian Ellacott自2017年12月起担任Belmont Instrument首席执行官；2013年7月至2017年9月担任Laborie Medical Technology首席执行官。
- Brian Ellacott,Chief Executive of Officer Belmont Instrument since December 2017; Chief Executive Officer of Laborie Medical Technology July 2013 to September 2017.
- Steve Forte
-
Steve Forte自2019年10月起担任首席财务官执行Vice President。在加入我们之前，他曾于2018年8月至2019年6月担任Clementia PharmaceuticalsInc.首席财务官，在此期间，Clementia被Ipsen S.A.收购，2015年9月至2018年8月，福特担任Thinking Capital Financial Corporation首席财务官，他是一家加拿大金融技术公司，在那里他最终领导公司通过出售目的投资。从2014年9月到2015年9月，他曾担任CST Canada Co.的财务执行董事。从2005年到2014年，Forte先生在Aptalis Pharma Inc.担任越来越重要的职务，包括最近担任财务报告Vice President，负责该公司的整体公司控制职能。他目前任职于Profound MedicalCorp.董事会，在那里他也是审计委员会的成员。Forte先生在康科迪亚大学（Concordia University）获得会计学商业学士学位，是魁北克省（Qu&233；BEC）的一名注册专业会计师，也是一名不在ISACA执业的注册信息系统审计师。
Steve Forte has served as our Executive Vice President, Chief Financial Officer since October 2019. Prior to joining us, he served as Chief Financial Officer of Clementia Pharmaceuticals Inc. from August 2018 through June 2019 during which time Clementia was acquired by Ipsen S.A. From September 2015 to August 2018 Mr. Forte served as Chief Financial Officer of Thinking Capital Financial Corporation, a Canadian financial technology firm, where he ultimately led the firm through a sale to Purpose Investments. From September 2014 to September 2015 he served as Executive Director of Finance of CST Canada Co. From 2005 to 2014 Mr. Forte held positions of increasing responsibility at Aptalis Pharma Inc., including most recently holding the position of Vice President, Financial Reporting where he was responsible for the overall corporate controllership function of the company. He currently serves on the board of directors of Profound Medical Corp., where he is also a member of the audit committee. Mr. Forte received his Bachelor of Commerce in accountancy from Concordia University and is a Certified Professional Accountant in the Province of Québec and a Certified Information Systems Auditor non-practicing with ISACA. - Steve Forte自2019年10月起担任首席财务官执行Vice President。在加入我们之前，他曾于2018年8月至2019年6月担任Clementia PharmaceuticalsInc.首席财务官，在此期间，Clementia被Ipsen S.A.收购，2015年9月至2018年8月，福特担任Thinking Capital Financial Corporation首席财务官，他是一家加拿大金融技术公司，在那里他最终领导公司通过出售目的投资。从2014年9月到2015年9月，他曾担任CST Canada Co.的财务执行董事。从2005年到2014年，Forte先生在Aptalis Pharma Inc.担任越来越重要的职务，包括最近担任财务报告Vice President，负责该公司的整体公司控制职能。他目前任职于Profound MedicalCorp.董事会，在那里他也是审计委员会的成员。Forte先生在康科迪亚大学（Concordia University）获得会计学商业学士学位，是魁北克省（Qu&233；BEC）的一名注册专业会计师，也是一名不在ISACA执业的注册信息系统审计师。
- Steve Forte has served as our Executive Vice President, Chief Financial Officer since October 2019. Prior to joining us, he served as Chief Financial Officer of Clementia Pharmaceuticals Inc. from August 2018 through June 2019 during which time Clementia was acquired by Ipsen S.A. From September 2015 to August 2018 Mr. Forte served as Chief Financial Officer of Thinking Capital Financial Corporation, a Canadian financial technology firm, where he ultimately led the firm through a sale to Purpose Investments. From September 2014 to September 2015 he served as Executive Director of Finance of CST Canada Co. From 2005 to 2014 Mr. Forte held positions of increasing responsibility at Aptalis Pharma Inc., including most recently holding the position of Vice President, Financial Reporting where he was responsible for the overall corporate controllership function of the company. He currently serves on the board of directors of Profound Medical Corp., where he is also a member of the audit committee. Mr. Forte received his Bachelor of Commerce in accountancy from Concordia University and is a Certified Professional Accountant in the Province of Québec and a Certified Information Systems Auditor non-practicing with ISACA.
- Linda Maxwell
-
Linda Maxwell，自2005年起担任外科医生；自2015年6月起担任Ryerson大学生物医学区执行主任；牛津大学技术转让经理（2013年6月至2014年7月）。
Linda Maxwell,Surgeon since 2005; Executive Director of Biomedical Zone Ryerson University since June 2015; Technology Transfer Manager at University of Oxford (June 2013 to July 2014). - Linda Maxwell，自2005年起担任外科医生；自2015年6月起担任Ryerson大学生物医学区执行主任；牛津大学技术转让经理（2013年6月至2014年7月）。
- Linda Maxwell,Surgeon since 2005; Executive Director of Biomedical Zone Ryerson University since June 2015; Technology Transfer Manager at University of Oxford (June 2013 to July 2014).
- Arthur Rosenthal
-
Arthur Rosenthal是LivaNova PLC的董事兼薪酬委员会主席，该公司是一家英国的全球性医疗技术公司。在此之前，Rosenthal博士于2007年1月至2015年10月担任Cyberonics董事会非执行董事兼薪酬委员会主席。Rosenthal博士从2010年6月开始担任波士顿大学（Boston University）生物医学工程系的实践教授。自2011年12月起，Rosenthal博士还担任Geyecue，Ltd.的首席执行官，该公司由他联合创立，该公司是一家发展阶段的医疗设备公司，致力于下消化道和上消化道癌症筛查的引导活检。Rosenthal从2011年6月到2012年7月担任Cappella Medical Devices Ltd.（现为Arravasc Ltd.，一家处于发展阶段的公司，专注于冠状动脉疾病的新型设备解决方案）执行副董事长。从2009年6月到2011年6月，Rosenthal博士担任Cappella，Inc.的总裁兼首席执行官。Rosenthal博士从2002年1月开始担任LabCoat，Ltd.的董事长，从2005年1月开始担任首席执行官，直到2008年12月该公司被波士顿科学国际有限公司收购。从1994年1月到2000年5月，Rosenthal博士是波士顿科学公司（Boston Scientific）的高级副总裁，企业官和首席发展官，从2000年5月到2005年1月退休，他是波士顿科学公司（Boston Scientific）的高级副总裁，首席科学官和执行委员会成员。Rosenthal从2000年到2010年担任Renovo，Ltd.（一家英国制药公司，于2006年上市）非执行董事，从2006年到2009年担任薪酬委员会主席。Rosenthal于2009年7月加入Interface Biologics，Inc.（多伦多一家专注于药物输送设备的开发阶段公司）董事会，担任非执行董事。2011年4月，Rosenthal博士被选为Interface Biologics，Inc.的董事长。从2013年4月至2015年5月，Rosenthal博士担任Arch Technologies，Inc.的非执行董事兼薪酬委员会成员，目前是Arch’；的临床咨询委员会成员。2015年，Rosenthal博士被任命为爱尔兰高威Curam National University的工业咨询委员会成员。Rosenthal博士从2003年开始担任美国医学与生物工程研究所（American Institute of Medical and Biological Engineering）的研究员。
Arthur Rosenthal is director and Chair of Compensation Committee for LivaNova PLC, a UK global medical technology company. Prior, Dr. Rosenthal served on the Cyberonics board of directors as a non-executive director and Chair of the Compensation Committee from January 2007 to October 2015. Since June 2010 Dr. Rosenthal has served as Professor of Practice in the Biomedical Engineering Department at Boston University. Since December 2011 Dr. Rosenthal has also served as CEO of gEyeCue, Ltd., which he co-founded, a development stage medical device company working on a guided biopsy for lower and upper gastrointestinal cancer screening. From June 2011 until July 2012 Dr. Rosenthal served as executive vice chairman of Cappella Medical Devices Ltd. now ArraVasc Ltd., a development-stage company focused on novel device solutions for coronary artery disease. From June 2009 until June 2011 Dr. Rosenthal served as President and CEO of Cappella, Inc. Dr. Rosenthal served as chairman, from January 2002 and CEO, commencing in January 2005 of Labcoat, Ltd. until its acquisition by Boston Scientific Corporation in December 2008. From January 1994 to May 2000 Dr. Rosenthal was a Senior Vice President, Corporate Officer, and Chief Development Officer of Boston Scientific, and from May 2000 until his retirement in January 2005 he was a Senior Vice President, Chief Scientific Officer, and Executive Committee Member of Boston Scientific. From 2000 until 2010 Dr. Rosenthal served as a non-executive director, and from 2006 through 2009 as chairman of the Remuneration Committee, of Renovo, Ltd., a U.K. based pharmaceutical company that became publicly traded in 2006. In July 2009 Dr. Rosenthal joined the board of Interface Biologics, Inc., a Toronto-based development stage company focused on drug delivery devices, as a non-executive director. In April 2011 Dr. Rosenthal was elected Chairman at Interface Biologics, Inc. From April 2013 to May 2015 Dr. Rosenthal served as non-executive director and Member of the Compensation Committee of Arch Technologies, Inc. and is currently a member of Arch’s Clinical Advisory Board. In 2015 Dr. Rosenthal was appointed to the Industrial Advisory Committee, CURAM National University in Galway, Ireland. Since 2003 Dr. Rosenthal has been a Fellow of the American Institute of Medical and Biological Engineering. - Arthur Rosenthal是LivaNova PLC的董事兼薪酬委员会主席，该公司是一家英国的全球性医疗技术公司。在此之前，Rosenthal博士于2007年1月至2015年10月担任Cyberonics董事会非执行董事兼薪酬委员会主席。Rosenthal博士从2010年6月开始担任波士顿大学（Boston University）生物医学工程系的实践教授。自2011年12月起，Rosenthal博士还担任Geyecue，Ltd.的首席执行官，该公司由他联合创立，该公司是一家发展阶段的医疗设备公司，致力于下消化道和上消化道癌症筛查的引导活检。Rosenthal从2011年6月到2012年7月担任Cappella Medical Devices Ltd.（现为Arravasc Ltd.，一家处于发展阶段的公司，专注于冠状动脉疾病的新型设备解决方案）执行副董事长。从2009年6月到2011年6月，Rosenthal博士担任Cappella，Inc.的总裁兼首席执行官。Rosenthal博士从2002年1月开始担任LabCoat，Ltd.的董事长，从2005年1月开始担任首席执行官，直到2008年12月该公司被波士顿科学国际有限公司收购。从1994年1月到2000年5月，Rosenthal博士是波士顿科学公司（Boston Scientific）的高级副总裁，企业官和首席发展官，从2000年5月到2005年1月退休，他是波士顿科学公司（Boston Scientific）的高级副总裁，首席科学官和执行委员会成员。Rosenthal从2000年到2010年担任Renovo，Ltd.（一家英国制药公司，于2006年上市）非执行董事，从2006年到2009年担任薪酬委员会主席。Rosenthal于2009年7月加入Interface Biologics，Inc.（多伦多一家专注于药物输送设备的开发阶段公司）董事会，担任非执行董事。2011年4月，Rosenthal博士被选为Interface Biologics，Inc.的董事长。从2013年4月至2015年5月，Rosenthal博士担任Arch Technologies，Inc.的非执行董事兼薪酬委员会成员，目前是Arch’；的临床咨询委员会成员。2015年，Rosenthal博士被任命为爱尔兰高威Curam National University的工业咨询委员会成员。Rosenthal博士从2003年开始担任美国医学与生物工程研究所（American Institute of Medical and Biological Engineering）的研究员。
- Arthur Rosenthal is director and Chair of Compensation Committee for LivaNova PLC, a UK global medical technology company. Prior, Dr. Rosenthal served on the Cyberonics board of directors as a non-executive director and Chair of the Compensation Committee from January 2007 to October 2015. Since June 2010 Dr. Rosenthal has served as Professor of Practice in the Biomedical Engineering Department at Boston University. Since December 2011 Dr. Rosenthal has also served as CEO of gEyeCue, Ltd., which he co-founded, a development stage medical device company working on a guided biopsy for lower and upper gastrointestinal cancer screening. From June 2011 until July 2012 Dr. Rosenthal served as executive vice chairman of Cappella Medical Devices Ltd. now ArraVasc Ltd., a development-stage company focused on novel device solutions for coronary artery disease. From June 2009 until June 2011 Dr. Rosenthal served as President and CEO of Cappella, Inc. Dr. Rosenthal served as chairman, from January 2002 and CEO, commencing in January 2005 of Labcoat, Ltd. until its acquisition by Boston Scientific Corporation in December 2008. From January 1994 to May 2000 Dr. Rosenthal was a Senior Vice President, Corporate Officer, and Chief Development Officer of Boston Scientific, and from May 2000 until his retirement in January 2005 he was a Senior Vice President, Chief Scientific Officer, and Executive Committee Member of Boston Scientific. From 2000 until 2010 Dr. Rosenthal served as a non-executive director, and from 2006 through 2009 as chairman of the Remuneration Committee, of Renovo, Ltd., a U.K. based pharmaceutical company that became publicly traded in 2006. In July 2009 Dr. Rosenthal joined the board of Interface Biologics, Inc., a Toronto-based development stage company focused on drug delivery devices, as a non-executive director. In April 2011 Dr. Rosenthal was elected Chairman at Interface Biologics, Inc. From April 2013 to May 2015 Dr. Rosenthal served as non-executive director and Member of the Compensation Committee of Arch Technologies, Inc. and is currently a member of Arch’s Clinical Advisory Board. In 2015 Dr. Rosenthal was appointed to the Industrial Advisory Committee, CURAM National University in Galway, Ireland. Since 2003 Dr. Rosenthal has been a Fellow of the American Institute of Medical and Biological Engineering.
- Kenneth Galbraith
-
Kenneth Galbraith历任Zymeworks Bc.总裁、首席执行官兼Zymeworks Bc.董事会主席至2022年1月。Galbraith先生是Five Corners Capital，Inc.的董事总经理，该公司是他于2013年创立的。最近，他于2021年4月至2022年1月在Syncona有限公司担任驻场执行官。2019年4月至2020年11月，他担任上市公司Liminal BioSciences Inc.（前身为Prometic Life Sciences Inc.）的首席执行官，并于2020年11月至2021年2月继续担任该公司的顾问。2017年6月至2019年4月，他还担任Fairhaven Pharmaceuticals Inc.的首席执行官。Galbraith先生于2008年7月至2022年1月担任MacroGenics，Inc.的董事，并于2017年1月起担任Profound Medical Corp.的董事，这两家公司都是上市公司。他还担任过几家私营公司的董事。此前，他于2007年加入Ventures West Capital，并于2013年创立了Five Corners Capital Inc.，负责管理Ventures West投资基金的持续运营。Galbraith先生在生物技术、医疗器械、制药和医疗保健等行业的公司担任执行董事、董事、投资者和顾问等职务时拥有30多年的经验。Galbraith先生在不列颠哥伦比亚大学获得了Comm.学士学位。Galbraith先生居住在联合王国剑桥。
Kenneth Galbraith,has served as Zymeworks Inc. Chief Executive Officer and Chair of Zymeworks Inc. Board of Directors since January 2022. In addition, Mr. Galbraith has served as Zymeworks Inc. President since June 2023 and previously served as Zymeworks Inc. President from January 2022 to August 2022, and served as Zymeworks Inc. interim Chief Financial Officer from April 2024 to September 2024. Mr. Galbraith was a Managing Director at Five Corners Capital, Inc., which he founded in 2013, from February 2021 until January 2022. He served as Executive in Residence at Syncona Limited from April 2021 until January 2022, and has served as an advisor to Syncona since May 2023. He served as Chief Executive Officer of Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.), a publicly held company, from April 2019 to November 2020, continuing as an advisor to that company from November 2020 to February 2021. He also served as Chief Executive Officer of Fairhaven Pharmaceuticals Inc. from June 2017 to April 2019. Mr. Galbraith has served as a director of several publicly held companies, including MacroGenics, Inc. from July 2008 until January 2022, Profound Medical Corp. from January 2017 to May 2023, and Celator Pharmaceuticals, Inc. from July 2008 to October 2013. He has also served as a director of several privately held companies. Previously, he joined Ventures West Capital in 2007 and founded Five Corners Capital Inc. in 2013 to manage the continued operations of the Ventures West Investment Funds. Mr. Galbraith has over 35 years of experience serving as an executive, director, investor and adviser to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr. Galbraith received his B.Comm. from the University of British Columbia. - Kenneth Galbraith历任Zymeworks Bc.总裁、首席执行官兼Zymeworks Bc.董事会主席至2022年1月。Galbraith先生是Five Corners Capital，Inc.的董事总经理，该公司是他于2013年创立的。最近，他于2021年4月至2022年1月在Syncona有限公司担任驻场执行官。2019年4月至2020年11月，他担任上市公司Liminal BioSciences Inc.（前身为Prometic Life Sciences Inc.）的首席执行官，并于2020年11月至2021年2月继续担任该公司的顾问。2017年6月至2019年4月，他还担任Fairhaven Pharmaceuticals Inc.的首席执行官。Galbraith先生于2008年7月至2022年1月担任MacroGenics，Inc.的董事，并于2017年1月起担任Profound Medical Corp.的董事，这两家公司都是上市公司。他还担任过几家私营公司的董事。此前，他于2007年加入Ventures West Capital，并于2013年创立了Five Corners Capital Inc.，负责管理Ventures West投资基金的持续运营。Galbraith先生在生物技术、医疗器械、制药和医疗保健等行业的公司担任执行董事、董事、投资者和顾问等职务时拥有30多年的经验。Galbraith先生在不列颠哥伦比亚大学获得了Comm.学士学位。Galbraith先生居住在联合王国剑桥。
- Kenneth Galbraith,has served as Zymeworks Inc. Chief Executive Officer and Chair of Zymeworks Inc. Board of Directors since January 2022. In addition, Mr. Galbraith has served as Zymeworks Inc. President since June 2023 and previously served as Zymeworks Inc. President from January 2022 to August 2022, and served as Zymeworks Inc. interim Chief Financial Officer from April 2024 to September 2024. Mr. Galbraith was a Managing Director at Five Corners Capital, Inc., which he founded in 2013, from February 2021 until January 2022. He served as Executive in Residence at Syncona Limited from April 2021 until January 2022, and has served as an advisor to Syncona since May 2023. He served as Chief Executive Officer of Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.), a publicly held company, from April 2019 to November 2020, continuing as an advisor to that company from November 2020 to February 2021. He also served as Chief Executive Officer of Fairhaven Pharmaceuticals Inc. from June 2017 to April 2019. Mr. Galbraith has served as a director of several publicly held companies, including MacroGenics, Inc. from July 2008 until January 2022, Profound Medical Corp. from January 2017 to May 2023, and Celator Pharmaceuticals, Inc. from July 2008 to October 2013. He has also served as a director of several privately held companies. Previously, he joined Ventures West Capital in 2007 and founded Five Corners Capital Inc. in 2013 to manage the continued operations of the Ventures West Investment Funds. Mr. Galbraith has over 35 years of experience serving as an executive, director, investor and adviser to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr. Galbraith received his B.Comm. from the University of British Columbia.
- Kenneth Galbraith
-
Kenneth Galbraith， ，他是特许会计师学会会员，是董事。2010年1月以来，他一直担任我们的董事。2013年9月以来，他一直担任Five Corners Capital公司的董事总经理。他此前曾担任Ventures West公司的普通合伙人，领导公司的生物技术实践（从2007年到2013年）。加入Ventures West公司之前，他曾担任AnorMED公司（生物制药公司，专注于血液学、艾滋病毒和肿瘤领域的新的治疗产品）的主席兼临时首席执行官（直到其以价值近6亿美元的现金出售给Genzyme公司）。此前，他曾担任QLT公司（全球生物制药公司，专门从事开发治疗眼睛疾病）的高级管理职务13年，并于2000年退任执行副总裁和首席财务官。他目前任职于许多私营生物技术公司、以及 MacroGenics公司（纳斯达克上市的生物技术公司，MGNX）的董事会。他持有the University of British Columbia 的荣誉商业学士学位。他也是加拿大不列颠哥伦比亚省注册会计师。
Kenneth Galbraith has served as our Chief Executive Officer since April 2019 and a member of our board of directors since August 2016. Mr. Galbraith is also Managing Director of Five Corners Capital. Mr. Galbraith joined Ventures West as a General Partner in September 2007 and led the firm's biotechnology practice prior to founding Five Corners Capital in September 2013 to continue managing the Ventures West investment portfolio. Previously, Mr. Galbraith served as the Chairman and Interim CEO of AnorMED, until its sale to Genzyme Corp. in November 2006. Starting in the biotechnology sector in 1987 Mr. Galbraith spent 13 years in senior management with QLT Inc., retiring in 2000 from his position as Executive VP and CFO. Mr. Galbraith currently serves on the board of directors of Macrogenics and Profound Medical Inc., both of which are Nasdaq-listed healthcare companies. Mr. Galbraith earned a Bachelor of Commerce Honours degree from the University of British Columbia in 1985 and was appointed a Fellow of the Chartered Accountants of BC in 2013. - Kenneth Galbraith， ，他是特许会计师学会会员，是董事。2010年1月以来，他一直担任我们的董事。2013年9月以来，他一直担任Five Corners Capital公司的董事总经理。他此前曾担任Ventures West公司的普通合伙人，领导公司的生物技术实践（从2007年到2013年）。加入Ventures West公司之前，他曾担任AnorMED公司（生物制药公司，专注于血液学、艾滋病毒和肿瘤领域的新的治疗产品）的主席兼临时首席执行官（直到其以价值近6亿美元的现金出售给Genzyme公司）。此前，他曾担任QLT公司（全球生物制药公司，专门从事开发治疗眼睛疾病）的高级管理职务13年，并于2000年退任执行副总裁和首席财务官。他目前任职于许多私营生物技术公司、以及 MacroGenics公司（纳斯达克上市的生物技术公司，MGNX）的董事会。他持有the University of British Columbia 的荣誉商业学士学位。他也是加拿大不列颠哥伦比亚省注册会计师。
- Kenneth Galbraith has served as our Chief Executive Officer since April 2019 and a member of our board of directors since August 2016. Mr. Galbraith is also Managing Director of Five Corners Capital. Mr. Galbraith joined Ventures West as a General Partner in September 2007 and led the firm's biotechnology practice prior to founding Five Corners Capital in September 2013 to continue managing the Ventures West investment portfolio. Previously, Mr. Galbraith served as the Chairman and Interim CEO of AnorMED, until its sale to Genzyme Corp. in November 2006. Starting in the biotechnology sector in 1987 Mr. Galbraith spent 13 years in senior management with QLT Inc., retiring in 2000 from his position as Executive VP and CFO. Mr. Galbraith currently serves on the board of directors of Macrogenics and Profound Medical Inc., both of which are Nasdaq-listed healthcare companies. Mr. Galbraith earned a Bachelor of Commerce Honours degree from the University of British Columbia in 1985 and was appointed a Fellow of the Chartered Accountants of BC in 2013.
高管简历
中英对照 | 中文 | 英文- Arun Menawat
Arun Menawat，自2016年8月起担任公司首席执行官兼董事；2003年至2016年担任Novadaq TechnologiesInc.董事长，总裁兼首席执行官。
Arun Menawat,Chief Executive Officer and Director of the Company since August 2016; Chairman, President and Chief Executive Officer of Novadaq Technologies Inc. from 2003 to 2016.- Arun Menawat，自2016年8月起担任公司首席执行官兼董事；2003年至2016年担任Novadaq TechnologiesInc.董事长，总裁兼首席执行官。
- Arun Menawat,Chief Executive Officer and Director of the Company since August 2016; Chairman, President and Chief Executive Officer of Novadaq Technologies Inc. from 2003 to 2016.
- Mathieu Burtnyk
Mathieu Burtnyk，自2019年7月1日起担任Profect Medical Inc.临床事务Vice President。
Mathieu Burtnyk,Vice President of Clinical Affairs, Profound Medical Inc. since July 1 2019.- Mathieu Burtnyk，自2019年7月1日起担任Profect Medical Inc.临床事务Vice President。
- Mathieu Burtnyk,Vice President of Clinical Affairs, Profound Medical Inc. since July 1 2019.
- Aaron Davidson
自2018年5月3日起担任Profect Medical Inc.首席财务官兼企业发展高级副总裁Aaron Davidson；2004年1月至2018年5月2日担任H.I.G.联席主管兼董事总经理。
Aaron Davidson,Chief Financial Officer and SVP of Corporate Development, Profound Medical Inc. since May 3 2018; Co-Head and Managing Director of H.I.G. from January 2004 to May 2 2018.- 自2018年5月3日起担任Profect Medical Inc.首席财务官兼企业发展高级副总裁Aaron Davidson；2004年1月至2018年5月2日担任H.I.G.联席主管兼董事总经理。
- Aaron Davidson,Chief Financial Officer and SVP of Corporate Development, Profound Medical Inc. since May 3 2018; Co-Head and Managing Director of H.I.G. from January 2004 to May 2 2018.
- Rashed Dewan
Rashed Dewan，自2015年11月17日起担任Profect Medical Inc.财务Vice President；
Rashed Dewan,Vice President of Finance, Profound Medical Inc. since November 17 2015; Corporate Controller of Profound Medical Inc. since July 6 2015.- Rashed Dewan，自2015年11月17日起担任Profect Medical Inc.财务Vice President；
- Rashed Dewan,Vice President of Finance, Profound Medical Inc. since November 17 2015; Corporate Controller of Profound Medical Inc. since July 6 2015.
- Guruprit Singh
Guruprit Singh，自2011年12月1日起担任Profect Medical Inc.法规事务和产品管理Vice President。
Guruprit Singh,Vice President of Regulatory Affairs and Product Management, Profound Medical Inc. since December 1 2011.- Guruprit Singh，自2011年12月1日起担任Profect Medical Inc.法规事务和产品管理Vice President。
- Guruprit Singh,Vice President of Regulatory Affairs and Product Management, Profound Medical Inc. since December 1 2011.
- Aaron Davidson
Aaron Davidson先生自2006年6月就担任董事会成员。自2004年，Davidson先生担任H.I.G. BioVentures的常务董事，主要负责生命科学领域的投资机会。在2004年前，Davidson先生担任Ventures West副总裁，该公司是一家风险投资公司，主要涉及关注生命科学的公司的风险投资。Davidson在美国礼来制药公司开始自己的职业生涯，该公司是一家上市医药公司。在那里的十年里，Davidson担任过在美国和加拿大的各种管理角色，其中包括业务拓展，策略规划，市场调查和财务计划。Davidson先生目前是许多私企董事会的董事，同时也是Novadaq Technologies Inc董事会的董事。Davidson先生之前是Tranzyme Pharm董事会成员，现在是Ocera Therapeutics Inc董事会成员，直到2013年。Davidson先生在加拿大麦吉尔大学取得商业学士学位，在哈佛大学商学院取得工商管理学硕士学位。
Aaron Davidson. Mr. Davidson has served as a member of our board of directors since June 2006. Since 2004 Mr. Davidson has served as a Managing Director of H.I.G. BioVentures and focuses on investment opportunities in the life sciences sector. Prior to 2004 Mr. Davidson served as a Vice President with Ventures West, a venture capital firm, with a focus on venture investing in life science companies. Mr. Davidson began his career with Eli Lilly and Company, a publicly-traded pharmaceutical company, where he spent a decade in various management roles in the United States and Canada, including business development, strategic planning, market research and financial planning. Mr. Davidson currently serves as a director on numerous private company boards of directors and on the board of directors Novadaq Technologies Inc. Mr. Davidson previously served on the board of directors of Tranzyme Pharm, now Ocera Therapeutics Inc, until 2013. Mr. Davidson currently serves on the boards of Alder Biopharmaceuticals Inc., Cardeas Pharma, HyperBranch Medical Technology, Intact Vascular, NeurAxon Inc., and NOVADAQ. He served on the board of Salmedix and Gemin X Pharmaceuticals prior to their acquisitions by Cephalonin in 2005 and 2011 respectively, and on the board of Oncogenex Pharmaceuticals prior to its public listing. Mr. Davidson holds an M.B.A. from Harvard Business School and a Bachelor of Commerce from McGill University.- Aaron Davidson先生自2006年6月就担任董事会成员。自2004年，Davidson先生担任H.I.G. BioVentures的常务董事，主要负责生命科学领域的投资机会。在2004年前，Davidson先生担任Ventures West副总裁，该公司是一家风险投资公司，主要涉及关注生命科学的公司的风险投资。Davidson在美国礼来制药公司开始自己的职业生涯，该公司是一家上市医药公司。在那里的十年里，Davidson担任过在美国和加拿大的各种管理角色，其中包括业务拓展，策略规划，市场调查和财务计划。Davidson先生目前是许多私企董事会的董事，同时也是Novadaq Technologies Inc董事会的董事。Davidson先生之前是Tranzyme Pharm董事会成员，现在是Ocera Therapeutics Inc董事会成员，直到2013年。Davidson先生在加拿大麦吉尔大学取得商业学士学位，在哈佛大学商学院取得工商管理学硕士学位。
- Aaron Davidson. Mr. Davidson has served as a member of our board of directors since June 2006. Since 2004 Mr. Davidson has served as a Managing Director of H.I.G. BioVentures and focuses on investment opportunities in the life sciences sector. Prior to 2004 Mr. Davidson served as a Vice President with Ventures West, a venture capital firm, with a focus on venture investing in life science companies. Mr. Davidson began his career with Eli Lilly and Company, a publicly-traded pharmaceutical company, where he spent a decade in various management roles in the United States and Canada, including business development, strategic planning, market research and financial planning. Mr. Davidson currently serves as a director on numerous private company boards of directors and on the board of directors Novadaq Technologies Inc. Mr. Davidson previously served on the board of directors of Tranzyme Pharm, now Ocera Therapeutics Inc, until 2013. Mr. Davidson currently serves on the boards of Alder Biopharmaceuticals Inc., Cardeas Pharma, HyperBranch Medical Technology, Intact Vascular, NeurAxon Inc., and NOVADAQ. He served on the board of Salmedix and Gemin X Pharmaceuticals prior to their acquisitions by Cephalonin in 2005 and 2011 respectively, and on the board of Oncogenex Pharmaceuticals prior to its public listing. Mr. Davidson holds an M.B.A. from Harvard Business School and a Bachelor of Commerce from McGill University.